Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 2
2005 3
2006 4
2007 5
2008 5
2009 4
2010 3
2011 2
2012 3
2013 2
2014 4
2015 6
2016 7
2017 8
2018 3
2019 4
2020 1
2021 6
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant.
Ryu DK, Song R, Kim M, Kim YI, Kim C, Kim JI, Kwon KS, Tijsma AS, Nuijten PM, van Baalen CA, Hermanus T, Kgagudi P, Moyo-Gwete T, Moore PL, Choi YK, Lee SY. Ryu DK, et al. Among authors: kim c. Biochem Biophys Res Commun. 2021 Aug 20;566:135-140. doi: 10.1016/j.bbrc.2021.06.016. Epub 2021 Jun 7. Biochem Biophys Res Commun. 2021. PMID: 34119826 Free PMC article.
Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study.
Hastie KM, Li H, Bedinger D, Schendel SL, Dennison SM, Li K, Rayaprolu V, Yu X, Mann C, Zandonatti M, Diaz Avalos R, Zyla D, Buck T, Hui S, Shaffer K, Hariharan C, Yin J, Olmedillas E, Enriquez A, Parekh D, Abraha M, Feeney E, Horn GQ; CoVIC-DB team1; Aldon Y, Ali H, Aracic S, Cobb RR, Federman RS, Fernandez JM, Glanville J, Green R, Grigoryan G, Lujan Hernandez AG, Ho DD, Huang KA, Ingraham J, Jiang W, Kellam P, Kim C, Kim M, Kim HM, Kong C, Krebs SJ, Lan F, Lang G, Lee S, Leung CL, Liu J, Lu Y, MacCamy A, McGuire AT, Palser AL, Rabbitts TH, Rikhtegaran Tehrani Z, Sajadi MM, Sanders RW, Sato AK, Schweizer L, Seo J, Shen B, Snitselaar JL, Stamatatos L, Tan Y, Tomic MT, van Gils MJ, Youssef S, Yu J, Yuan TZ, Zhang Q, Peters B, Tomaras GD, Germann T, Saphire EO. Hastie KM, et al. Among authors: kim c. Science. 2021 Oct 22;374(6566):472-478. doi: 10.1126/science.abh2315. Epub 2021 Sep 23. Science. 2021. PMID: 34554826 Free PMC article.
A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein.
Kim C, Ryu DK, Lee J, Kim YI, Seo JM, Kim YG, Jeong JH, Kim M, Kim JI, Kim P, Bae JS, Shim EY, Lee MS, Kim MS, Noh H, Park GS, Park JS, Son D, An Y, Lee JN, Kwon KS, Lee JY, Lee H, Yang JS, Kim KC, Kim SS, Woo HM, Kim JW, Park MS, Yu KM, Kim SM, Kim EH, Park SJ, Jeong ST, Yu CH, Song Y, Gu SH, Oh H, Koo BS, Hong JJ, Ryu CM, Park WB, Oh MD, Choi YK, Lee SY. Kim C, et al. Nat Commun. 2021 Jan 12;12(1):288. doi: 10.1038/s41467-020-20602-5. Nat Commun. 2021. PMID: 33436577 Free PMC article.
The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2.
Ryu DK, Kang B, Noh H, Woo SJ, Lee MH, Nuijten PM, Kim JI, Seo JM, Kim C, Kim M, Yang E, Lim G, Kim SG, Eo SK, Choi JA, Song M, Oh SS, Chung HY, Tijsma AS, van Baalen CA, Kwon KS, Lee SY. Ryu DK, et al. Among authors: kim c. Biochem Biophys Res Commun. 2021 Nov 12;578:91-96. doi: 10.1016/j.bbrc.2021.09.023. Epub 2021 Sep 13. Biochem Biophys Res Commun. 2021. PMID: 34547629 Free PMC article.
Stable nebulization and muco-trapping properties of regdanvimab/IN-006 support its development as a potent, dose-saving inhaled therapy for COVID-19.
McSweeney MD, Stewart I, Richardson Z, Kang H, Park Y, Kim C, Tiruthani K, Wolf W, Schaefer A, Kumar P, Aurora H, Hutchins J, Cho JM, Hickey AJ, Lee SY, Lai SK. McSweeney MD, et al. Among authors: kim c. Bioeng Transl Med. 2022 Aug 30;8(1):e10391. doi: 10.1002/btm2.10391. Online ahead of print. Bioeng Transl Med. 2022. PMID: 36248234 Free PMC article.
Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Seo JM, Kang B, Song R, Noh H, Kim C, Kim JI, Kim M, Ryu DK, Lee MH, Yang JS, Kim KC, Lee JY, Lee H, Woo HM, Kim JW, Choi JA, Song M, Tomaszewska-Kiecana M, Wołowik A, Kulesza A, Kim S, Ahn K, Jung N, Lee SY. Seo JM, et al. Among authors: kim c. Emerg Microbes Infect. 2022 Dec;11(1):2315-2325. doi: 10.1080/22221751.2022.2117094. Emerg Microbes Infect. 2022. PMID: 36006772 Free PMC article. Clinical Trial.
60 results